A multiple sclerosis disease progression measure based on cumulative disability

被引:2
|
作者
Manouchehrinia, Ali [1 ]
Kingwell, Elaine [2 ,3 ]
Zhu, Feng [2 ,3 ]
Tremlett, Helen [2 ,3 ]
Hillert, Jan [1 ]
Ramanujam, Ryan [1 ,4 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp Solna, Dept Clin Neurosci, Stockholm, Sweden
[2] Univ British Columbia, UBC Hosp, Fac Med Neurol, Vancouver, BC, Canada
[3] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada
[4] Royal Inst Technol, Dept Math, Stockholm, Sweden
基金
加拿大健康研究院;
关键词
Multiple sclerosis; progression measure; outcome; disability;
D O I
10.1177/1352458520988632
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Existing severity measurements in multiple sclerosis (MS) are often cross-sectional, making longitudinal comparisons of disease course between individuals difficult. Objective: The objective of this study is to create a severity metric that can reliably summarize a patient's disease course. Methods: We developed the nARMSS - normalized ARMSS (age-related MS severity score) over follow-up, using the deviation of individual ARMSS scores from the expected value and integrated over the corresponding time period. The nARMSS scales from -5 to +5; a positive value indicates a more severe disease course for a patient when compared to other patients with similar disease timings. Results: Using Swedish MS registry data, the nARMSS was tested using data at 2 and 4 years of follow-up to predict the most severe quartile during the subsequent period up to 10 years total follow-up. The metric used was area under the curve of the receiver operating characteristic (AUC-ROC). This resulted in measurements of 0.929 and 0.941. In an external Canadian validation cohort, the equivalent AUC-ROCs were 0.901 and 0.908. Conclusion: The nARMSS provides a reliable, generalizable and easily measurable metric which makes longitudinal comparison of disease course between individuals feasible.
引用
收藏
页码:1875 / 1883
页数:9
相关论文
共 50 条
  • [1] Measuring disability progression in multiple sclerosis
    Achiron, Anat
    JOURNAL OF NEUROLOGY, 2006, 253 (Suppl 6) : 31 - 36
  • [2] Measuring disability progression in multiple sclerosis
    Anat Achiron
    Journal of Neurology, 2006, 253 : vi31 - vi36
  • [3] Lipids in multiple sclerosis: adverse lipid profiles, disability and disease progression
    Tettey, Prudence
    van der Mei, Ingrid A. F.
    CLINICAL LIPIDOLOGY, 2014, 9 (05) : 473 - 475
  • [4] Smoking and disability progression in multiple sclerosis
    Hedstrom, Anna Karin
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2020, 20 (08) : 739 - 741
  • [5] Disability progression in aggressive multiple sclerosis
    Menon, Suresh
    Zhu, Feng
    Shirani, Afsaneh
    Oger, Joel
    Freedman, Mark S.
    Tremlett, Helen
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (03) : 456 - 463
  • [6] Serum NSE level and disability progression in multiple sclerosis
    Koch, Marcus W.
    George, Suzanne
    Wall, Winona
    Yong, V. Wee
    Metz, Luanne M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 350 (1-2) : 46 - 50
  • [7] Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability
    Ana Paula Kallaur
    Sayonara Rangel Oliveira
    Andréa Name Colado Simão
    Daniela Frizon Alfieri
    Tamires Flauzino
    Josiane Lopes
    Wildea Lice de Carvalho Jennings Pereira
    Caio de Meleck Proença
    Sueli Donizete Borelli
    Damacio Ramón Kaimen-Maciel
    Michael Maes
    Edna Maria Vissoci Reiche
    Molecular Neurobiology, 2017, 54 : 2950 - 2960
  • [8] Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability
    Kallaur, Ana Paula
    Oliveira, Sayonara Rangel
    Colado Simao, Andrea Name
    Alfieri, Daniela Frizon
    Flauzino, Tamires
    Lopes, Josiane
    de Carvalho Jennings Pereira, Wildea Lice
    Proenca, Caio de Meleck
    Borelli, Sueli Donizete
    Kaimen-Maciel, Damacio Ramon
    Maes, Michael
    Vissoci Reiche, Edna Maria
    MOLECULAR NEUROBIOLOGY, 2017, 54 (04) : 2950 - 2960
  • [9] Disease activity impacts disability progression in primary progressive multiple sclerosis
    Marrodan, M.
    Bensi, C.
    Pappolla, A.
    Rojas, J. I.
    Gaitan, M. I.
    Ysrraelit, M. C.
    Negrotto, L.
    Fiol, M. P.
    Patrucco, L.
    Cristiano, E.
    Farez, M. F.
    Correale, J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
  • [10] Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability
    Flachenecker, P
    Reiners, K
    Krauser, M
    Wolf, A
    Toyka, KV
    MULTIPLE SCLEROSIS, 2001, 7 (05): : 327 - 334